Phase II study of the efficacy and safety of palbociclib in patients with recurrent ovarian cancer

By afschroeder • August 22, 2025

Konecny GE, Davidson TM, Lebreton CL, Marsh LA, Chetram DK, Atkinson HJ, Larson MC, Oberg AL, Abdelaal N, Silverstein J, Jatoi A, Washburn A, Burton J, Dowdy S, Zhang L, Hallberg D, Velculescu VE, Slamon DJ, Wahner-Hendrickson AE. Phase II study of the efficacy and safety of palbociclib in patients with recurrent ovarian cancer. Int J Gynecol Cancer. 2025 Jul 28;35(10):102028. doi: 10.1016/j.ijgc.2025.102028. Epub ahead of print. PMID: 40839974.

Tags: CDK4/6 inhibitor, Cyclin-Dependent Kinases, Fellow, Hematology/Oncology, ovarian cancer, Palbociclib, Publications, targeted therapy

Author Correction: Barcoded HIV-1 reveals viral persistence driven by clonal proliferation and distinct epigenetic patterns

Zhang TH, Shi Y, Komarova NL, Wodarz D, Kostelny M, Gonzales A, Abbaali I, Chen H, Bresson-Tan G, Dimapasoc M, Harvey W, Oh C, Carmona[...]

Final safety and efficacy results from a phase 1/2 study of tagraxofusp, a CD123-targeted therapy, for myelofibrosis

Yacoub A, Ali H, Gupta V, Wang ES, Patnaik MM, Schiller GJ, Taparia M, Mughal TI, Lindsay R, Galleu A, Gupta I, Pemmaraju N. Final[...]

Treatment of Liver Metastases from Uveal Melanoma with Percutaneous Hepatic Perfusion

Padia SA, Modi S, Wehrenberg-Klee E, Adamo RD, Ahmed A, Orloff M, Helmerhorst HJF, Chmielowski B, Ozkan OS, Burgmans MC, Grözinger MG, Lewandowski RJ, Krishnasamy[...]